Wall Street brokerages expect AngioDynamics, Inc. (NASDAQ:ANGO) to announce sales of $86.13 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for AngioDynamics’ earnings, with the highest sales estimate coming in at $88.78 million and the lowest estimate coming in at $84.60 million. AngioDynamics reported sales of $85.60 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 0.6%. The firm is expected to report its next earnings report before the market opens on Thursday, March 29th.
According to Zacks, analysts expect that AngioDynamics will report full-year sales of $86.13 million for the current fiscal year, with estimates ranging from $346.84 million to $352.27 million. For the next fiscal year, analysts forecast that the firm will report sales of $355.89 million per share, with estimates ranging from $350.30 million to $361.78 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. The firm had revenue of $86.70 million for the quarter, compared to analysts’ expectations of $88.15 million. During the same quarter last year, the firm posted $0.19 EPS. The company’s revenue was down 2.6% compared to the same quarter last year.
Several analysts have weighed in on ANGO shares. BidaskClub raised AngioDynamics from a “sell” rating to a “hold” rating in a report on Thursday, February 22nd. Craig Hallum cut AngioDynamics from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Zacks Investment Research raised AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a report on Monday, January 22nd. Finally, TheStreet cut AngioDynamics from a “b-” rating to a “c” rating in a report on Tuesday, January 2nd. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $18.60.
Shares of AngioDynamics (ANGO) opened at $16.69 on Thursday. AngioDynamics has a 1-year low of $14.80 and a 1-year high of $18.85. The firm has a market capitalization of $613.28, a PE ratio of 25.29, a price-to-earnings-growth ratio of 1.55 and a beta of 1.00. The company has a quick ratio of 1.65, a current ratio of 2.56 and a debt-to-equity ratio of 0.17.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its holdings in shares of AngioDynamics by 0.9% during the 3rd quarter. Wells Fargo & Company MN now owns 1,025,233 shares of the medical instruments supplier’s stock valued at $17,521,000 after buying an additional 9,639 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of AngioDynamics by 32.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,321 shares of the medical instruments supplier’s stock valued at $475,000 after buying an additional 7,130 shares in the last quarter. Bessemer Group Inc. raised its holdings in shares of AngioDynamics by 13.9% during the 3rd quarter. Bessemer Group Inc. now owns 63,200 shares of the medical instruments supplier’s stock valued at $1,080,000 after buying an additional 7,700 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of AngioDynamics by 14.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,938,115 shares of the medical instruments supplier’s stock valued at $31,416,000 after buying an additional 243,825 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of AngioDynamics by 5.6% during the 3rd quarter. Principal Financial Group Inc. now owns 293,833 shares of the medical instruments supplier’s stock valued at $5,022,000 after buying an additional 15,637 shares in the last quarter. 95.62% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Anticipate AngioDynamics, Inc. (ANGO) Will Post Quarterly Sales of $86.13 Million” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/15/zacks-analysts-anticipate-angiodynamics-inc-ango-will-post-quarterly-sales-of-86-13-million.html.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Get a free copy of the Zacks research report on AngioDynamics (ANGO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.